Drug Profile
Research programme: myocardial reperfusion injury therapeutics - RegeneRx/University of Maryland
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator RegeneRx Biopharmaceuticals; University of Maryland, Baltimore
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Reperfusion injury
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Reperfusion-injury(Prevention) in USA
- 26 Mar 2015 RegeneRx receives patent acceptance notice for thymosin beta-4 in Israel
- 25 Feb 2015 RegeneRx has patent protection for prevention, treatment and repair of heart damage in Israel